Introduction: In nonneurogenic female bladder outlet obstruction (BOO), management goals include reduction of outlet resistance to increase urinary outflow and improve bladder voiding to prevent or reduce lower and upper urinary tract (LUT and UUT) function deterioration, by correcting the underlying etiology. As significant progress has been achieved in the conservative and pharmacological management of nonneurogenic female BOO, the purpose of this article is to review and summarize the current literature.
Materials And Methods: For this narrative review, a PubMed® search was performed by cross-referencing the keywords "female bladder outlet obstruction," "female voiding dysfunction," "conservative management," "pharmacological management," and "treatment" with various terms related to the management of female BOO. Clinical practice guidelines and landmark reviews from the most renowned experts in the field were also used.
Management: This review discusses and summarizes the conservative and pharmacological management of nonneurogenic female BOO based on the most relevant data currently available in the literature.
Conclusion: The recent advances in the understanding of underlying mechanisms involved in female BOO allow for more individualized management. Conservative and pharmacological options show interesting outcomes, particularly in the context of a functional cause of BOO. Overall, the level of evidence is still low regarding the use of conservative and pharmacological measures and more long-term data are required.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665770 | PMC |
| http://dx.doi.org/10.1002/nau.25318 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment Crossover Following Advanced Therapy for Overactive Bladder Syndrome.
Urogynecology (Phila)
February 2025
From the Departments of Gynecology and Obstetrics.
Importance: Patients deciding between advanced therapies for overactive bladder syndrome may be interested to know the likelihood of treatment crossover after sacral neuromodulation, intradetrusor OnabotulinumtoxinA, or percutaneous tibial nerve stimulation. Treatment crossover was defined as a switch from one advanced therapy to another.
Objectives: The aim of this study was to estimate the rate of treatment crossover after each advanced therapy for nonneurogenic overactive bladder syndrome.
Comparison of the 3-Year Continuation Rate and Discontinuation Factors Between Vibegron and Mirabegron in Patients With Overactive Bladder: A Retrospective Follow-Up Study in a Rehabilitation Hospital in Japan.
Low Urin Tract Symptoms
January 2025
Department of Urology, Hyogo Prefectural Central Rehabilitation Hospital, Kobe, Hyogo, Japan.
Objectives: The objective of this study is to compare the 3-year continuation rate and discontinuation factors between vibegron and mirabegron in patients with overactive bladder in a rehabilitation hospital in Japan.
Methods: The 3-year continuation rate of the target drugs and reasons for discontinuation as well as patients' backgrounds and adverse effects were evaluated retrospectively from the medical records between September 2018 and December 2020. After selecting patients according to our inclusion and exclusion criteria, 136 cases taking mirabegron and 82 taking vibegron were adjusted for intergroup variability by propensity score matching.
Assessing the Knowledge of ChatGPT in Answering Questions Regarding Female Urology.
Urol J
November 2024
Department of Urology, Haseki Training and Research Hospital, Istanbul, Turkey.
Purpose: With the recent increase in the use of artificial intelligence in the medical field, this study aimed to evaluate the accuracy and adequacy of ChatGPT's responses to questions related to female urology.
Methods: Intensive internet research was performed to prepare a frequently asked question (FAQs) list. Scientific questions were created in accordance with the European Urology Association (EAU) Non-neurogenic Female Lower Urinary Tract Symptoms Guidelines, EAU Chronic Pelvis Pain Guidelines, and EAU Neuro-Urology Guidelines.
OnabotulinumA toxin injections: A novel option for management of refractory nocturnal enuresis.
J Pediatr Urol
October 2024
Department of Urology, Atrium Health Wake Forest Baptist, Winston Salem, NC, 27101, USA. Electronic address:
Introduction: While not entirely understood, nocturnal enuresis (NE) has been considered pathophysiologically distinct from other non-neurogenic voiding disorders. We believe that a significant component of the pathology is due to bladder overactivity. Intravesical Onabotulinumtoxin A (OBTA) injections are utilized in overactive bladder management.
View Article and Find Full Text PDFLong-term Outcomes of Periurethral Sphincter Botulinum Toxin in Female Chronic Urinary Retention.
Int Neurourol J
September 2024
Department of Uro Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Article Synopsis
- Nonneurogenic chronic urinary retention is rare in young women, with Fowler syndrome being a primary cause, and while treatments like sacral neuromodulation are ideal, they aren't commonly accessible.
- A retrospective study reviewed 33 women treated with botulinum toxin A (BoTX-A) injections to address urinary retention due to Fowler syndrome over an 11-year period, finding that 64% of recipients responded positively after the treatment.
- The study concluded that periurethral botulinum toxin injections are a safe and effective long-term solution for managing this condition, offering a viable option when other treatments are unavailable.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!